3h
Hosted on MSNArcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares ...
Age at initiation of treatment and the type of biologic therapy prescribed effect the rate of drug survival among patients with psoriasis.
Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the population and is mediated ...
Published results showed “Latine” patients with psoriasis in the U.S. have unique experiences with their disease and ...
Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal ...
The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.
The drug offered more relief than a placebo in clinical trials, though it does not appear more effective than other pain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results